Prestigious award recognizes breakthrough innovations transforming sleep health
WASHINGTON, June 17, 2025 /PRNewswire/ — The National Sleep Foundation (NSF) is now accepting applications for its prestigious SleepTech® Award which recognizes the year’s most innovative achievements in sleep technology. The application deadline is September 26, 2025, with winners to be announced in October 2025.
The SleepTech Award is given in two categories: Sleep Health and Wellness, which includes products and services consumers can use as part of their daily routine for sleep and health; and Sleep Disorders and Conditions, which includes solutions that seek to improve the patient experience for diagnosis and treatment.
“The SleepTech Award represents our commitment to advancing sleep technology that’s based in science and insight to make meaningful improvements in people’s lives,” said John Lopos, CEO of the National Sleep Foundation. “We’re looking for innovations for sleep health that connect cutting edge research, thoughtful design, and practical, accessible solutions for all kinds of users.” Lopos added.
The most recent winners of the SleepTech Award include UBlockout, Loop Earplugs, and Neurovalens.
A $500 application fee applies, though this fee is waived for members of NSF’s SleepTech® Network. To apply for the 2025 SleepTech Award or learn more about eligibility requirements, visit www.theNSF.org/SleepTech-Award/.
About the National Sleep Foundation
There’s only one National Sleep Foundation (NSF). NSF is an independent 501(c)3 nonprofit organization dedicated to improving health and well-being through sleep education and advocacy. Founded in 1990, the NSF is committed to advancing excellence in sleep health theory, research and practice. In its 35 years, NSF has promoted sleep health through expert recommendations, consensus guidelines, tech standards, and easy-to-use tips and tools to improve sleep. For more information about NSF, visit www.theNSF.org │ SleepHealthJournal.org
SOURCE National Sleep Foundation
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…